PRIMARY ANALYSIS OF GEICO 120/DORA, A REALWORLD MULTICENTRE STUDY OF DOSTARLIMAB IN PATIENTS WITH RECURRENT OR ADVANCED DNA MISMATCH REPAIR DEFICIENT/MICROSATELLITE INSTABILITY-HIGH (DMMR/MSI-H) ENDOMETRIAL CANCER

This article has no abstract
Epistemonikos ID: cdd854c93c89a473b66c3f7a27458887966aa0d5
First added on: Mar 08, 2025